Cost-effectiveness of Strength Exercise or Aerobic Exercise Compared with Usual Care for Patients with Knee Osteoarthritis: Secondary Results from a Multiarm Randomised Controlled Trial in Norway

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 May 28

PMID 38803266

Authors

Rikke Munk Killingmo

Britt Elin Oiestad

May-Arna Risberg

Esther Maas

Margreth Grotle

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the 1-year cost-effectiveness of strength exercise or aerobic exercise compared with usual care for patients with symptomatic knee osteoarthritis (OA), from a societal and healthcare perspective.

Design: Cost-effectiveness analysis embedded in a three-arm randomised controlled trial.

Participants And Setting: A total of 161 people with symptomatic knee OA seeking Norwegian primary or secondary care were included in the analyses.

Interventions: Participants were randomised to either 12 weeks of strength exercise (n=54), 12 weeks of aerobic exercise (n=53) or usual care (n=54).

Outcome Measures: Quality-adjusted life-years (QALYs) estimated by the EuroQol-5 Dimensions-5 Levels, and costs related to healthcare utilisation and productivity loss estimated in euros (€), aggregated for 1 year of follow-up. Cost-effectiveness was expressed with mean incremental cost-effectiveness ratios (ICERs). Bootstrapping was used to estimate ICER uncertainty.

Results: From a 1-year societal perspective, the mean cost per patient was €7954, €8101 and €17 398 in the strength exercise, aerobic exercise and usual care group, respectively. From a 1-year healthcare perspective, the mean cost per patient was €848, €2003 and €1654 in the strength exercise, aerobic exercise and usual care group, respectively. Mean differences in costs significantly favoured strength exercise and aerobic exercise from a 1-year societal perspective and strength exercise from a 1-year healthcare perspective. There were no significant differences in mean QALYs between groups. From a 1-year societal perspective, at a willingness-to-pay threshold of €27 500, the probability of strength exercise or aerobic exercise being cost-effective was ≥98%. From a 1-year healthcare perspective, the probability of strength exercise or aerobic exercise being cost-effective was ≥97% and ≥76%, respectively.

Conclusion: From a 1-year societal and healthcare perspective, a 12-week strength exercise or aerobic exercise programme is cost-effective compared with usual care in patients with symptomatic knee OA.

Trial Registration Number: NCT01682980.

References

Bannuru R, Osani M, Vaysbrot E, Arden N, Bennell K, Bierma-Zeinstra S . OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11):1578-1589. DOI: 10.1016/j.joca.2019.06.011. View

Mazzei D, Ademola A, Abbott J, Sajobi T, Hildebrand K, Marshall D . Are education, exercise and diet interventions a cost-effective treatment to manage hip and knee osteoarthritis? A systematic review. Osteoarthritis Cartilage. 2020; 29(4):456-470. DOI: 10.1016/j.joca.2020.10.002. View

Hiligsmann M, Cooper C, Guillemin F, Hochberg M, Tugwell P, Arden N . A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014; 44(3):271-82. DOI: 10.1016/j.semarthrit.2014.06.005. View

Sanders G, Maciejewski M, Basu A . Overview of Cost-effectiveness Analysis. JAMA. 2019; 321(14):1400-1401. DOI: 10.1001/jama.2019.1265. View

Pinto D, Robertson M, Hansen P, Abbott J . Cost-effectiveness of nonpharmacologic, nonsurgical interventions for hip and/or knee osteoarthritis: systematic review. Value Health. 2012; 15(1):1-12. DOI: 10.1016/j.jval.2011.09.003. View

Hunger M, Schwarzkopf L, Heier M, Peters A, Holle R . Official statistics and claims data records indicate non-response and recall bias within survey-based estimates of health care utilization in the older population. BMC Health Serv Res. 2013; 13:1. PMC: 3545728. DOI: 10.1186/1472-6963-13-1. View

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10):1727-36. PMC: 3220807. DOI: 10.1007/s11136-011-9903-x. View

van Ginkel J, Linting M, Rippe R, van der Voort A . Rebutting Existing Misconceptions About Multiple Imputation as a Method for Handling Missing Data. J Pers Assess. 2019; 102(3):297-308. DOI: 10.1080/00223891.2018.1530680. View

Kim D, Basu A . How Does Cost-Effectiveness Analysis Inform Health Care Decisions?. AMA J Ethics. 2021; 23(8):E639-647. DOI: 10.1001/amajethics.2021.639. View

10.

Goh S, Persson M, Stocks J, Hou Y, Lin J, Hall M . Efficacy and potential determinants of exercise therapy in knee and hip osteoarthritis: A systematic review and meta-analysis. Ann Phys Rehabil Med. 2019; 62(5):356-365. PMC: 6880792. DOI: 10.1016/j.rehab.2019.04.006. View

11.

Mutubuki E, El Alili M, Bosmans J, Oosterhuis T, Snoek F, Ostelo R . The statistical approach in trial-based economic evaluations matters: get your statistics together!. BMC Health Serv Res. 2021; 21(1):475. PMC: 8135982. DOI: 10.1186/s12913-021-06513-1. View

12.

Ramsey S, Willke R, Glick H, Reed S, Augustovski F, Jonsson B . Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015; 18(2):161-72. DOI: 10.1016/j.jval.2015.02.001. View

13.

Allen K . Cost-effectiveness of physical activity and exercise therapy programs for knee osteoarthritis: making the case for health plan coverage. Osteoarthritis Cartilage. 2020; 28(6):719-720. PMC: 10513134. DOI: 10.1016/j.joca.2020.02.833. View

14.

Kolasinski S, Neogi T, Hochberg M, Oatis C, Guyatt G, Block J . 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020; 72(2):220-233. PMC: 10518852. DOI: 10.1002/art.41142. View

15.

Hunter D, Bierma-Zeinstra S . Osteoarthritis. Lancet. 2019; 393(10182):1745-1759. DOI: 10.1016/S0140-6736(19)30417-9. View

16.

Salmon J, Rat A, Sellam J, Michel M, Eschard J, Guillemin F . Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthritis Cartilage. 2016; 24(9):1500-8. DOI: 10.1016/j.joca.2016.03.012. View

17.

Miyamoto G, Jornada Ben A, Bosmans J, Van Tulder M, Lin C, Cabral C . Interpretation of trial-based economic evaluations of musculoskeletal physical therapy interventions. Braz J Phys Ther. 2021; 25(5):514-529. PMC: 8536890. DOI: 10.1016/j.bjpt.2021.06.011. View

18.

Devlin N, Shah K, Feng Y, Mulhern B, van Hout B . Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2017; 27(1):7-22. PMC: 6680214. DOI: 10.1002/hec.3564. View

19.

Hunter D, Schofield D, Callander E . The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014; 10(7):437-41. DOI: 10.1038/nrrheum.2014.44. View

20.

Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H . Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2021; 29-30:100587. PMC: 7704420. DOI: 10.1016/j.eclinm.2020.100587. View